Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Toulon

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
International Journal of Laboratory Hematology|July 19, 2016
Developmental hemostasis: laboratory and clinical implicationsP Toulon
Annales De Biologie Clinique|October 17, 2001
[Clinical usefulness of global assays of the anticoagulant pathway of protein C]P Toulon
Annales De Biologie Clinique|October 1, 1998
[Hemostasis and human immunodeficiency virus (HIV) infection]P Toulon
Hematology/Oncology Clinics of North America|May 12, 2000
Screening for risk factors for thrombosis using a new generation of assays developed to evaluate the functionality of the protein C anticoagulant pathwayP Toulon, P Perez
Annales De Biologie Clinique|November 20, 2001
[Value of D-dimer measurement in the exclusion diagnosis of pulmonary embolism]C Lecourvoisier, P Toulon
Thrombosis Research|October 24, 2001
Sensitivity of the ProC global assay for protein C pathway abnormalities. clinical experience in 899 unselected patients with venous thromboembolismP Toulon, R Adda, P Perez
Journal of Chromatography|February 22, 1991
Purification of heparin cofactor II from human plasmaP Toulon, G Chadeuf, M Aiach
Clinica Chimica Acta; International Journal of Clinical Chemistry|January 31, 1992
An enzyme-linked immunosorbent assay for heparin cofactor II (HCII). Application to the measurement of HCII in clinical materialsP Toulon, J M Costa, J Amiral
Thrombosis and Haemostasis|November 30, 1990
Increased heparin cofactor II levels in women taking oral contraceptivesP Toulon, J M Bardin, N Blumenfeld
Stroke|October 1, 1996
Factor V Leiden mutation in cerebral venous thrombosisM Zuber, P Toulon, L Marnet, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
International Journal of Laboratory Hematology|July 19, 2016
Developmental hemostasis: laboratory and clinical implicationsP Toulon
Annales De Biologie Clinique|October 17, 2001
[Clinical usefulness of global assays of the anticoagulant pathway of protein C]P Toulon
Annales De Biologie Clinique|October 1, 1998
[Hemostasis and human immunodeficiency virus (HIV) infection]P Toulon
Hematology/Oncology Clinics of North America|May 12, 2000
Screening for risk factors for thrombosis using a new generation of assays developed to evaluate the functionality of the protein C anticoagulant pathwayP Toulon, P Perez
Annales De Biologie Clinique|November 20, 2001
[Value of D-dimer measurement in the exclusion diagnosis of pulmonary embolism]C Lecourvoisier, P Toulon
Thrombosis Research|October 24, 2001
Sensitivity of the ProC global assay for protein C pathway abnormalities. clinical experience in 899 unselected patients with venous thromboembolismP Toulon, R Adda, P Perez
Journal of Chromatography|February 22, 1991
Purification of heparin cofactor II from human plasmaP Toulon, G Chadeuf, M Aiach
Clinica Chimica Acta; International Journal of Clinical Chemistry|January 31, 1992
An enzyme-linked immunosorbent assay for heparin cofactor II (HCII). Application to the measurement of HCII in clinical materialsP Toulon, J M Costa, J Amiral
Thrombosis and Haemostasis|November 30, 1990
Increased heparin cofactor II levels in women taking oral contraceptivesP Toulon, J M Bardin, N Blumenfeld
Stroke|October 1, 1996
Factor V Leiden mutation in cerebral venous thrombosisM Zuber, P Toulon, L Marnet, et al.
Pageof 4